Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Kyverna Therapeutics Names Warner Biddle CEO
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies Remains a Buy on Gilead Sciences (GILD)
This 'Forgotten Child' Is One of the Best Biotech Plays: Analyst
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
Hold Rating on Gilead Sciences Amid Lenacapavir's Promise and Market Uncertainties
Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 5.7% Return On Equity?
Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD)
Gilead Sciences Insider Sold Shares Worth $2,459,577, According to a Recent SEC Filing
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $90
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Daily short sale tracking: Warner Bros Discovery's short volume increased by 4 million, with a short sale ratio of 16%
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
Express News | Marengo Therapeutics: Under Agreement, Gilead Will Provide Trodelvy to Marengo
Marengo Therapeutics Announces Clinical Study Collaboration With Gilead Sciences to Evaluate Invikafusp Alfa (STAR0602) and Trodelvy in Both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating
Buy Rating Affirmed for Gilead Sciences on Lenacapavir's Market-Changing Potential in PrEP